ClinicalTrials.gg
CompletedNCT02195869Updated Jul 11, 2019Results posted

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease

A Phase 1/2 interventional study of Ibrutinib in Graft Versus Host Disease, sponsored by Pharmacyclics LLC.. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-11.

Primary conditionBronchiolitis Obliterans SyndromeRegistry: Graft vs Host DiseaseReclassifiedWhy we changed it
Registry
Graft vs Host Disease — the first condition term the registry derived for this study.
ClinicalTrials.gg
Bronchiolitis Obliterans Syndrome
Why
  1. The study's title name Bronchiolitis Obliterans Syndrome, a narrower term within Graft vs Host Disease.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing ibrutinib in Bronchiolitis Obliterans Syndrome — none open to participants now, 1 under way, 1 of them phase 3. ibrutinib · Bronchiolitis Obliterans Syndrome.

Enrollment
5th of 11
45 · median 19
Started
2014
the only one that year
Phase 1/2
3 of 11
none open now
Registered
3rd of 11
by date
Lead sponsor
4 of 11
Pharmacyclics LLC.

Among the 11 studies testing ibrutinib in Bronchiolitis Obliterans Syndrome, this one is the 5th largest by enrollment, is the only one that started in 2014, is one of 3 in phase 1/2, and was the 3rd registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

None of the 11 studies testing ibrutinib in Bronchiolitis Obliterans Syndrome is open now. The open studies under Bronchiolitis Obliterans Syndrome, anywhere →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing ibrutinib in Bronchiolitis Obliterans Syndrome as a file.
02

Study summary

The purpose of this study is to assess the safety and clinical efficacy of ibrutinib in subjects with steroid dependent or refractory Chronic Graft Versus Host Disease.

03

Conditions studied

  • Graft Versus Host Disease

Browse trials for

Keywords

  • PCYC1129
  • PCYC1129CA
  • 1129
  • Ibrutinib
  • PCI32765
  • IMBRUVICA
  • Pharmacyclics
  • PCYC
  • GVHD
  • Steroid dependent
  • refractory
  • chronic
  • graft versus host disease
  • chronic graft versus host disease
  • immunology
04

In context

Bronchiolitis Obliterans Syndrome Reclassified

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

This study's enrollment of 45 is close to the median of 50 across 565 interventional studies indexed under Bronchiolitis Obliterans Syndrome.

Browse Bronchiolitis Obliterans Syndrome studies →

Lead sponsor

Pharmacyclics LLC. is the lead sponsor of 54 studies on the registry; none are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.

First submitted before Pharmacyclics LLC. became part of AbbVie.

Compared within Bronchiolitis Obliterans Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Graft vs Host Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • dependent or classic chronic disease.
  • No more than 3 previous treatments for cGVHD.
  • Receiving baseline systemic glucocorticoid therapy (at stable dose) for cGVHD at study entry.
  • Men and women ≥18 years old.
  • performance status ≥60.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected active acute .
  • Current treatment with sirolimus AND either cyclosporine or tacrolimus.
  • History of treatment with a tyrosine kinase inhibitor (eg, imatinib), purine analogs or other cancer chemotherapy in the 4 weeks prior to starting study drug.
  • Currently active, cardiovascular disease.
  • Uncontrolled infections not responsive to antibiotics, antiviral medicines, or antifungal medicines or a recent infection requiring systemic treatment that was completed ≤14 days before the first dose of study drug.
  • Progressive underlying malignant disease including post-transplant lymphoproliferative disease.
  • History of other (not including the underlying malignancy that was the indication for transplant)
  • Concomitant use of warfarin or other Vitamin K antagonists
  • Known bleeding disorders or hemophilia.
  • History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
  • Known history of (HIV) or active with virus (HCV) or virus (HBV).
  • Concurrent use of a strong cytochrome P450(CYP) 3A inhibitor.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Phase 1b: Dose Level 1

    Subjects receive daily dose of 420 mg of Ibrutinib capsules

    Drug: Ibrutinib

  • Experimental
    Phase 1b: Dose Level 2

    Subjects receive daily dose of 280 mg of Ibrutinib capsules

    Drug: Ibrutinib

  • Experimental
    Phase 1b: Dose Level 3

    Subjects receive daily dose of 140 mg of Ibrutinib capsules

    Drug: Ibrutinib

  • Experimental
    Phase 2

    Subjects receive daily dose of recommended phase 2 dose

    Drug: Ibrutinib

Interventions

07

What researchers measure

Primary outcomes

  1. Phase 1b: To Evaluate the Safety and Tolerability of Ibrutinib in Steroid Dependent/Refractory cGVHD.

    Number of participants with dose-limiting toxicities as a measure of safety profile to determine recommended dose of ibrutinib

    Time frame: 28 treatment days after last subject enrolled in Phase 1 dose level(s).

  2. Phase 2: Overall Response Rate as the Percentage of Participants With Response

    Overall Response Rate is defined as the proportion of subjects who achieved complete response (CR) or partial response (PR). Response criteria are based on NIH cGVHD Response assessment (Pavletic 2006; Measurement of Therapeutic Response, ASBMT Web site).

    Time frame: Analysis was conducted with the data extraction date of 15 Sep 2017, with a median follow-up time of 25.56 months.

Secondary outcomes

  1. Sustained Response Rate as the Percentage of Participants With Sustained Response

    For subjects who achieved an NIH-defined CR or PR, the proportion of subjects who achieved CR or PR that was sustained for at least 20 weeks (140 days). Intermittent SD was also acceptable.

    Time frame: Analysis was conducted with the data extraction date of 15 Sep 2017, with a median follow-up time of 25.56 months.

  2. To Evaluate the Clinical Efficacy of Ibrutinib in Steroid Dependent/Refractory cGVHD by Measuring: Duration of Response (DOR)

    For subjects who achieved an NIH-defined CR or PR, the interval between the date of initial documentation of a response and the date of first documented evidence of PD, death, or date of censoring if applicable.

    Time frame: Analysis was conducted with the data extraction date of 15 Sep 2017, with a median follow-up time of 25.56 months.

  3. Corticosteroid Requirement Changes Over Time

    Average daily corticosteroid dose assessed each week.

    Time frame: Analysis was conducted with the data extraction date of 15 Sep 2017, with a median follow-up time of 25.56 months.

  4. Percentage of Participants With Overall Improvement in Lee cGVHD Symptom Summary Score

    Subject reported improvement in symptom burden. The symptom burden will be measured according to the Lee cGVHD Symptom Scale. A change in \>7 points on the Lee cGVHD Symptom Scale will be considered significant and relates to improvement in quality of life. A score is calculated for each subscale by taking the mean of all items completed if more than 50% were answered and normalizing to a 0 to 100 scale. A total summary score is calculated as the average of these 7 subscales if at least 4 subscales have valid scores. There are 7 subscales (Skin, Energy, Lung, Eye, Nutrition, Mouth and Psychological) with ratings as follow: 0- Not at all, 1- Slightly, 2 Moderately, 3 Quite a bit, 4-Extremely; with a lower values representing a better outcome.

    Time frame: Analysis was conducted with the data extraction date of 15 Sep 2017, with a median follow-up time of 25.56 months.

  5. Phase 2b: To Evaluate the Safety and Tolerability of Ibrutinib in Steroid Dependent/Refractory cGVHD

    Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib

    Time frame: From first dose with study drug until 30 days after the last dose of study drug, up to 36.7 months

08

Results

Posted Jul 11, 2019

Participant flow

Participant flow — Overall Study
MilestonePhase 1b/Phase 2
Started42
All-treated population42
Completed0
Not completed42
Withdrew: Cgvhd progression5
Withdrew: Malignancy progression/relapse2
Withdrew: Adverse event15
Withdrew: Withdrawal by subject7
Withdrew: Physician decision4
Withdrew: Study terminated by sponsor7
Withdrew: Noncompliance with study drug2

Outcome measures

PrimaryPhase 1b: To Evaluate the Safety and Tolerability of Ibrutinib in Steroid Dependent/Refractory cGVHD.

Number of participants with dose-limiting toxicities as a measure of safety profile to determine recommended dose of ibrutinib

Time frame:
28 treatment days after last subject enrolled in Phase 1 dose level(s).
Reported as:
Count of participants · Participants
Phase 1b: To Evaluate the Safety and Tolerability of Ibrutinib in Steroid Dependent/Refractory cGVHD.
ParticipantsPhase 1b: Dose Level 1Phase 2
Phase 1b: To Evaluate the Safety and Tolerability of Ibrutinib in Steroid Dependent/Refractory cGVHD.0—
PrimaryPhase 2: Overall Response Rate as the Percentage of Participants With Response

Overall Response Rate is defined as the proportion of subjects who achieved complete response (CR) or partial response (PR). Response criteria are based on NIH cGVHD Response assessment (Pavletic 2006; Measurement of Therapeutic Response, ASBMT Web site).

Time frame:
Analysis was conducted with the data extraction date of 15 Sep 2017, with a median follow-up time of 25.56 months.
Reported as:
Number · percentage of participants
Phase 2: Overall Response Rate as the Percentage of Participants With Response
percentage of participantsPhase1b/Phase 2
Phase 2: Overall Response Rate as the Percentage of Participants With Response69 (52.9 to 82.4)
SecondarySustained Response Rate as the Percentage of Participants With Sustained Response

For subjects who achieved an NIH-defined CR or PR, the proportion of subjects who achieved CR or PR that was sustained for at least 20 weeks (140 days). Intermittent SD was also acceptable.

Time frame:
Analysis was conducted with the data extraction date of 15 Sep 2017, with a median follow-up time of 25.56 months.
Reported as:
Number · percentage of participants
Sustained Response Rate as the Percentage of Participants With Sustained Response
percentage of participantsPhase1b/Phase 2
Sustained Response Rate as the Percentage of Participants With Sustained Response69 (49.2 to 84.7)
SecondaryTo Evaluate the Clinical Efficacy of Ibrutinib in Steroid Dependent/Refractory cGVHD by Measuring: Duration of Response (DOR)

For subjects who achieved an NIH-defined CR or PR, the interval between the date of initial documentation of a response and the date of first documented evidence of PD, death, or date of censoring if applicable.

Time frame:
Analysis was conducted with the data extraction date of 15 Sep 2017, with a median follow-up time of 25.56 months.
Reported as:
Median · Median
To Evaluate the Clinical Efficacy of Ibrutinib in Steroid Dependent/Refractory cGVHD by Measuring: Duration of Response (DOR)
MedianPhase1b/Phase 2
To Evaluate the Clinical Efficacy of Ibrutinib in Steroid Dependent/Refractory cGVHD by Measuring: Duration of Response (DOR)NA (NA to NA)
SecondaryCorticosteroid Requirement Changes Over Time

Average daily corticosteroid dose assessed each week.

Time frame:
Analysis was conducted with the data extraction date of 15 Sep 2017, with a median follow-up time of 25.56 months.
Reported as:
Median · Daily Dose of Steroid by Weight (mg/kg/d
Corticosteroid Requirement Changes Over Time
Daily Dose of Steroid by Weight (mg/kg/dPhase 1b/Phase 2
Week 10.31 (0.06 to 1.3)
Week 20.32 (0.06 to 1.35)
Week 30.32 (0.06 to 1.35)
Week 40.31 (0.06 to 1.35)
Week 50.31 (0.06 to 1.53)
Week 60.30 (0.06 to 1.53)
Week 70.30 (0.06 to 1.53)
Week 80.30 (0.01 to 1.53)
Week 90.27 (0.00 to 1.03)
Week 100.25 (0.00 to 1.54)
Week 110.25 (0.00 to 2.02)
Week 120.25 (0.00 to 0.62)
Week 130.24 (0.00 to 0.62)
Week 140.23 (0.00 to 0.57)
Week 150.23 (0.00 to 0.58)
Week 160.23 (0.00 to 0.48)
Week 170.21 (0.00 to 0.47)
Week 180.20 (0.00 to 0.44)
Week 190.20 (0.00 to 0.44)
Week 200.21 (0.00 to 0.44)
Week 210.22 (0.00 to 0.37)
Week 220.22 (0.00 to 0.37)
Week 230.22 (0.00 to 0.60)
Week 240.21 (0.00 to 0.37)
Week 250.19 (0.00 to 0.38)
Week 260.18 (0.00 to 0.37)
Week 270.18 (0.00 to 0.37)
Week 280.18 (0.00 to 0.37)
Week 290.16 (0.00 to 0.37)
Week 300.16 (0.00 to 0.32)
Week 310.16 (0.00 to 0.29)
Week 320.18 (0.00 to 0.29)
Week 330.17 (0.00 to 0.29)
Week 340.17 (0.00 to 0.29)
Week 350.18 (0.00 to 0.29)
Week 360.18 (0.00 to 0.29)
Week 370.16 (0.00 to 0.29)
Week 380.15 (0.00 to 0.35)
Week 390.15 (0.00 to 0.30)
Week 400.15 (0.00 to 0.30)
Week 410.15 (0.00 to 0.30)
Week 420.15 (0.00 to 0.30)
Week 430.13 (0.00 to 0.30)
Week 440.13 (0.00 to 0.21)
Week 450.13 (0.00 to 0.21)
Week 460.13 (0.00 to 0.60)
Week 470.13 (0.00 to 0.60)
Week 480.13 (0.00 to 0.53)
Week 490.12 (0.00 to 0.46)
Week 500.10 (0.00 to 0.36)
Week 510.10 (0.00 to 0.24)
Week 520.10 (0.00 to 0.24)
Week 530.10 (0.00 to 0.24)
Week 540.10 (0.00 to 0.24)
Week 550.10 (0.00 to 0.24)
Week 560.10 (0.00 to 0.24)
Week 570.10 (0.00 to 0.24)
Week 580.10 (0.00 to 0.21)
Week 590.10 (0.00 to 0.27)
Week 600.08 (0.00 to 0.21)
Week 610.08 (0.00 to 0.21)
Week 620.08 (0.00 to 0.21)
Week 630.08 (0.00 to 0.21)
Week 640.08 (0.00 to 0.21)
Week 650.08 (0.00 to 0.21)
Week 660.08 (0.00 to 0.21)
Week 670.08 (0.00 to 0.21)
Week 680.08 (0.00 to 0.21)
Week 690.08 (0.00 to 0.21)
Week 700.08 (0.00 to 0.21)
Week 710.07 (0.00 to 0.21)
Week 720.08 (0.00 to 0.21)
Week 730.08 (0.00 to 0.21)
Week 740.07 (0.00 to 0.21)
Week 750.07 (0.00 to 0.20)
Week 760.07 (0.00 to 0.20)
Week 770.07 (0.00 to 0.20)
Week 780.07 (0.00 to 0.20)
Week 790.07 (0.00 to 0.20)
Week 800.07 (0.00 to 0.20)
Week 810.07 (0.00 to 0.27)
Week 820.07 (0.00 to 0.31)
Week 830.07 (0.00 to 0.31)
Week 840.07 (0.00 to 0.31)
Week 850.08 (0.00 to 0.31)
Week 860.08 (0.00 to 0.32)
Week 870.08 (0.00 to 0.32)
Week 880.08 (0.00 to 0.32)
Week 890.08 (0.00 to 0.95)
Week 900.08 (0.00 to 0.95)
Week 910.08 (0.00 to 0.95)
Week 920.08 (0.00 to 0.95)
Week 930.08 (0.00 to 0.95)
Week 940.08 (0.00 to 0.95)
Week 950.08 (0.00 to 0.95)
Week 960.08 (0.00 to 0.95)
Week 970.08 (0.00 to 0.95)
Week 980.08 (0.00 to 0.95)
Week 990.08 (0.00 to 0.95)
Week 1000.08 (0.00 to 0.95)
Week 1010.09 (0.00 to 0.95)
Week 1020.09 (0.00 to 0.95)
Week 1030.09 (0.00 to 0.95)
Week 1040.09 (0.00 to 0.95)
Week 1050.08 (0.00 to 0.95)
Week 1060.08 (0.00 to 0.95)
Week 1070.08 (0.00 to 0.95)
Week 1080.08 (0.00 to 0.95)
Week 1090.08 (0.00 to 0.95)
Week 1100.08 (0.00 to 0.95)
Week 1110.08 (0.00 to 0.95)
Week 1120.08 (0.00 to 0.95)
Week 1130.08 (0.00 to 0.95)
Week 1140.08 (0.00 to 0.95)
Week 1150.12 (0.00 to 0.95)
Week 1160.12 (0.00 to 0.95)
Week 1170.08 (0.00 to 0.95)
Week 1180.08 (0.00 to 0.95)
Week 1190.08 (0.00 to 0.95)
Week 1200.08 (0.00 to 0.95)
Week 1210.08 (0.00 to 0.95)
Week 1220.12 (0.00 to 0.95)
Week 1230.08 (0.00 to 0.22)
Week 1240.08 (0.00 to 0.22)
Week 1250.08 (0.00 to 0.22)
Week 1260.08 (0.00 to 0.22)
Week 1270.08 (0.00 to 0.22)
Week 1280.00 (0.00 to 0.22)
Week 1290.00 (0.00 to 0.22)
Week 1300.00 (0.00 to 0.22)
Week 1310.00 (0.00 to 0.19)
Week 1320.00 (0.00 to 0.15)
Week 1330.00 (0.00 to 0.15)
Week 1340.00 (0.00 to 0.15)
Week 1350.00 (0.00 to 0.15)
Week 1360.00 (0.00 to 0.15)
Week 1370.00 (0.00 to 0.15)
Week 1380.00 (0.00 to 0.15)
Week 1390.00 (0.00 to 0.15)
Week 1400.00 (0.00 to 0.15)
Week 1410.00 (0.00 to 0.16)
Week 1420.00 (0.00 to 0.17)
Week 1430.00 (0.00 to 0.17)
Week 1440.00 (0.00 to 0.17)
Week 1450.00 (0.00 to 0.17)
Week 1460.00 (0.00 to 0.17)
Week 1470.00 (0.00 to 0.17)
Week 1480.00 (0.00 to 0.17)
Week 1490.00 (0.00 to 0.17)
Week 1500.00 (0.00 to 0.17)
Week 1510.00 (0.00 to 0.17)
Week 1520.00 (0.00 to 0.17)
Week 1530.00 (0.00 to 0.15)
Week 1540.00 (0.00 to 0.14)
Week 1550.00 (0.00 to 0.14)
Week 1560.00 (0.00 to 0.14)
Week 1570.00 (0.00 to 0.13)
Week 1580.06 (0.00 to 0.11)
Week 1590.06 (0.00 to 0.11)
Week 1600.06 (0.00 to 0.11)
SecondaryPercentage of Participants With Overall Improvement in Lee cGVHD Symptom Summary Score

Subject reported improvement in symptom burden. The symptom burden will be measured according to the Lee cGVHD Symptom Scale. A change in \>7 points on the Lee cGVHD Symptom Scale will be considered significant and relates to improvement in quality of life. A score is calculated for each subscale by taking the mean of all items completed if more than 50% were answered and normalizing to a 0 to 100 scale. A total summary score is calculated as the average of these 7 subscales if at least 4 subscales have valid scores. There are 7 subscales (Skin, Energy, Lung, Eye, Nutrition, Mouth and Psychological) with ratings as follow: 0- Not at all, 1- Slightly, 2 Moderately, 3 Quite a bit, 4-Extremely; with a lower values representing a better outcome.

Time frame:
Analysis was conducted with the data extraction date of 15 Sep 2017, with a median follow-up time of 25.56 months.
Reported as:
Number · percentage of participants
Percentage of Participants With Overall Improvement in Lee cGVHD Symptom Summary Score
percentage of participantsPhase 1b/Phase 2
Percentage of Participants With Overall Improvement in Lee cGVHD Symptom Summary Score42.9 (27.7 to 59)
SecondaryPhase 2b: To Evaluate the Safety and Tolerability of Ibrutinib in Steroid Dependent/Refractory cGVHD

Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib

Time frame:
From first dose with study drug until 30 days after the last dose of study drug, up to 36.7 months
Reported as:
Count of participants · Participants
Phase 2b: To Evaluate the Safety and Tolerability of Ibrutinib in Steroid Dependent/Refractory cGVHD
ParticipantsPhase 1b/Phase 2
Phase 2b: To Evaluate the Safety and Tolerability of Ibrutinib in Steroid Dependent/Refractory cGVHD42

Adverse events

Collected over From first dose of study drug to within 30 days of last dose or starting subsequent therapy for cGVHD, up to 36.7 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase1b/Phase 27/42 (16.7%)22/42 (52.4%)41/42 (97.6%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventPhase1b/Phase 2
PneumoniaRespiratory, thoracic and mediastinal disorders6/42
CellulitisInfections and infestations2/42
DyspnoeaRespiratory, thoracic and mediastinal disorders2/42
HeadacheNervous system disorders2/42
Septic shockInfections and infestations2/42
Acute lymphocytic leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/42
AnaemiaBlood and lymphatic system disorders1/42
ArthralgiaMusculoskeletal and connective tissue disorders1/42
Atrial fibrilationCardiac disorders1/42
BacteraemiaInfections and infestations1/42
Most frequent other events
Showing 10 of 65
Most frequent other events
EventPhase1b/Phase 2
Gastrointestinal disordersGastrointestinal disorders38/42
General disorders and administration site conditionsGeneral disorders30/42
Infections and infestationsInfections and infestations25/42
FatiqueGeneral disorders24/42
Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders20/42
Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders19/42
Respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders18/42
Blood and lymphatic system disordersBlood and lymphatic system disorders17/42
DiarrhoeaGastrointestinal disorders17/42
Nervous system disordersNervous system disorders17/42

Baseline characteristics

Baseline analysis population includes all participants that received at least 1 dose of ibrutinib.

Age, Categorical
Age, Categorical(Participants)Phase 1b/Phase 2
<=18 years0
Between 18 and 65 years35
>=65 years7
Age, Continuous
Age, Continuous(years)Phase 1b/Phase 2
Mean50.5 ± 15.53
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1b/Phase 2
Female20
Male22
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1b/Phase 2
Hispanic or Latino2
Not Hispanic or Latino0
Unknown or Not Reported40
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1b/Phase 2
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American1
White39
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)Phase 1b/Phase 2
United States42
09

Study locations

10 sites
  • City of Hope Medical Center
    Duarte, California 91010, United States
  • University of California, San Francisco
    San Francisco, California 94143, United States
  • Stanford University
    Stanford, California 94305, United States
  • Emory University, Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
  • Vanderbilt University Medical Center, Henry-Joyce Cancer Clinic
    Nashville, Tennessee 37232, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
10

References and documents

Publications

  • Doki N, Toyosaki M, Shiratori S, Osumi T, Okada M, Kawakita T, Sawa M, Ishikawa T, Ueda Y, Yoshinari N, Nakahara S. An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease. Transplant Cell Ther. 2021 Oct;27(10):867.e1-867.e9. doi: 10.1016/j.jtct.2021.05.019. Epub 2021 Jun 6. PubMed 34102349 ↗
  • Waller EK, Miklos D, Cutler C, Arora M, Jagasia MH, Pusic I, Flowers MED, Logan AC, Nakamura R, Chang S, Clow F, Lal ID, Styles L, Jaglowski S. Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. Biol Blood Marrow Transplant. 2019 Oct;25(10):2002-2007. doi: 10.1016/j.bbmt.2019.06.023. Epub 2019 Jun 28. PubMed 31260802 ↗
  • Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, Flowers ME, Logan AC, Nakamura R, Blazar BR, Li Y, Chang S, Lal I, Dubovsky J, James DF, Styles L, Jaglowski S. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017 Nov 23;130(21):2243-2250. doi: 10.1182/blood-2017-07-793786. Epub 2017 Sep 18. PubMed 28924018 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2014 to primary completion in Sep 2017, 38 months.

Results were first posted in Jul 2019, 1 year 9 months after primary completion.

Of 24 phase 1/2 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 87. This study's 38 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2014
First posted
Jul 21, 2014
StartActual
Jul 14, 2014
Primary completionActual
Sep 15, 2017
CompletionActual
Sep 15, 2017
Results first posted
Jul 11, 2019
Last update
Jul 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02195869
Lead sponsor
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Jul 21, 2014
Start date
Jul 14, 2014
Primary completion
Sep 15, 2017
Completion
Sep 15, 2017
Results posted
Jul 11, 2019
Last update
Jul 11, 2019

Study contacts

Lori Styles, MD
study director · Pharmacyclics LLC.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion